Ceftazidime and Aranesp drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftazidime (ceftazidime) and Aranesp (darbepoetin alfa). Common drug interactions include tachycardia among females and hyperkalaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftazidime and Aranesp. It is created by eHealthMe based on reports of 36 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

On Aug, 05, 2026

36 people who take Ceftazidime and Aranesp together, and have interactions are studied.

Ceftazidime and Aranesp drug interactions.

What are the common drug interactions of Ceftazidime and Aranesp, by gender? *:

female:

Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Thrombosis (formation of a blood clot inside a blood vessel)
Tobacco abuse
Tricuspid valve incompetence (inefficient heart valve)
Urinary tract infection
Vomiting
Weight increased
Aortic arteriosclerosis (hardening of the aortic arteries)
Bradycardia (abnormally slow heart action)
Chest pain

male:

Hyperkalaemia (damage to or disease of the kidney)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Diarrhoea
Drug ineffective
Hepatitis cholestatic (flow of bile from the liver is slowed or blocked)
Histiocytosis haematophagic
Hyperthermia (body temperature greatly above normal)
Hypertriglyceridaemia (excess of triglycerides in the blood)
Hypoglobulinaemia (deficiency of globulin in the bloodstream)

What are the common drug interactions of Ceftazidime and Aranesp, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Dyspnoea (difficult or laboured respiration)
Swelling face
Urticaria (rash of round, red welts on the skin that itch intensely)

10-19:

n/a

20-29:

Abdominal pain upper
Asthenia (weakness)
Atelectasis (partial or complete collapse of the lung)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blood glucose increased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardiac failure congestive
Cardiomegaly (increased size of heart than normal)
Cardiomyopathy (weakening of the heart muscle)
Chest discomfort

30-39:

Hyperkalaemia (damage to or disease of the kidney)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Sudden death
Acute tonsillitis
Drug ineffective

40-49:

Oedema peripheral (superficial swelling)
Thrombocytopenia (decrease of platelets in blood)
Anaemia (lack of blood)
Anxiety
Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cellulitis (infection under the skin)
Diverticulum intestinal (a pouch that is attached to the first part of the small intestine)
Facet joint syndrome (problem with movement of the facet joints of the spine)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)

50-59:

Diarrhoea
Hepatitis cholestatic (flow of bile from the liver is slowed or blocked)
Histiocytosis haematophagic
Hyperthermia (body temperature greatly above normal)
Hypertriglyceridaemia (excess of triglycerides in the blood)
Hypoglobulinaemia (deficiency of globulin in the bloodstream)
Lymphoma (cancer that begins in immune system cells)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Microcytic anaemia (a generic term for any type of anaemia characterized by small red blood cells)
Multi-organ failure (multisystem organ failure)

60+:

Thrombocytopenia (decrease of platelets in blood)
Neutropenia (an abnormally low number of neutrophils)
Complications of transplanted kidney
Contusion (a type of hematoma of tissue in which capillaries)
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Sepsis (a severe blood infection that can lead to organ failure and death)
Tachycardia paroxysmal (a form of tachycardia which begins and ends in an acute (or paroxysmal) manner)
Urinary tract infection

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 8 people, 22.22%
Anaemia (lack of blood): 7 people, 19.44%
Haemorrhage (bleeding): 6 people, 16.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 6 people, 16.67%
Infection: 6 people, 16.67%
Itching: 6 people, 16.67%
Urinary Tract Infection: 6 people, 16.67%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 6 people, 16.67%
Rashes (redness): 6 people, 16.67%
Nausea (feeling of having an urge to vomit): 4 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and Aranesp?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously